206 related articles for article (PubMed ID: 10213232)
1. Cooperation between p53 and hMLH1 in a human colocarcinoma cell line in response to DNA damage.
Vikhanskaya F; Colella G; Valenti M; Parodi S; D'Incalci M; Broggini M
Clin Cancer Res; 1999 Apr; 5(4):937-41. PubMed ID: 10213232
[TBL] [Abstract][Full Text] [Related]
2. Spontaneous development of drug resistance: mismatch repair and p53 defects in resistance to cisplatin in human tumor cells.
Branch P; Masson M; Aquilina G; Bignami M; Karran P
Oncogene; 2000 Jun; 19(28):3138-45. PubMed ID: 10918568
[TBL] [Abstract][Full Text] [Related]
3. Mismatch repair and p53 independently affect sensitivity to N-(2-chloroethyl)-N'-cyclohexyl-N-nitrosourea.
Aquilina G; Ceccotti S; Martinelli S; Soddu S; Crescenzi M; Branch P; Karran P; Bignami M
Clin Cancer Res; 2000 Feb; 6(2):671-80. PubMed ID: 10690553
[TBL] [Abstract][Full Text] [Related]
4. Cells lacking CIP1/WAF1 genes exhibit preferential sensitivity to cisplatin and nitrogen mustard.
Fan S; Chang JK; Smith ML; Duba D; Fornace AJ; O'Connor PM
Oncogene; 1997 May; 14(18):2127-36. PubMed ID: 9174048
[TBL] [Abstract][Full Text] [Related]
5. P53 modulates the effect of loss of DNA mismatch repair on the sensitivity of human colon cancer cells to the cytotoxic and mutagenic effects of cisplatin.
Lin X; Ramamurthi K; Mishima M; Kondo A; Christen RD; Howell SB
Cancer Res; 2001 Feb; 61(4):1508-16. PubMed ID: 11245458
[TBL] [Abstract][Full Text] [Related]
6. Cellular effects of CPT-11 on colon carcinoma cells: dependence on p53 and hMLH1 status.
Magrini R; Bhonde MR; Hanski ML; Notter M; Scherübl H; Boland CR; Zeitz M; Hanski C
Int J Cancer; 2002 Sep; 101(1):23-31. PubMed ID: 12209584
[TBL] [Abstract][Full Text] [Related]
7. Human colon cancer cells surviving high doses of cisplatin or oxaliplatin in vitro are not defective in DNA mismatch repair proteins.
Sergent C; Franco N; Chapusot C; Lizard-Nacol S; Isambert N; Correia M; Chauffert B
Cancer Chemother Pharmacol; 2002 Jun; 49(6):445-52. PubMed ID: 12107548
[TBL] [Abstract][Full Text] [Related]
8. Effect of H(2)O(2) on cell cycle and survival in DNA mismatch repair-deficient and -proficient cell lines.
Chang DK; Goel A; Ricciardiello L; Lee DH; Chang CL; Carethers JM; Boland CR
Cancer Lett; 2003 Jun; 195(2):243-51. PubMed ID: 12767533
[TBL] [Abstract][Full Text] [Related]
9. Role of the hMLH1 DNA mismatch repair protein in fluoropyrimidine-mediated cell death and cell cycle responses.
Meyers M; Wagner MW; Hwang HS; Kinsella TJ; Boothman DA
Cancer Res; 2001 Jul; 61(13):5193-201. PubMed ID: 11431359
[TBL] [Abstract][Full Text] [Related]
10. Resistance to cytotoxic drugs in DNA mismatch repair-deficient cells.
Aebi S; Fink D; Gordon R; Kim HK; Zheng H; Fink JL; Howell SB
Clin Cancer Res; 1997 Oct; 3(10):1763-7. PubMed ID: 9815561
[TBL] [Abstract][Full Text] [Related]
11. Human chromosome 3 corrects mismatch repair deficiency and microsatellite instability and reduces N-methyl-N'-nitro-N-nitrosoguanidine tolerance in colon tumor cells with homozygous hMLH1 mutation.
Koi M; Umar A; Chauhan DP; Cherian SP; Carethers JM; Kunkel TA; Boland CR
Cancer Res; 1994 Aug; 54(16):4308-12. PubMed ID: 8044777
[TBL] [Abstract][Full Text] [Related]
12. Loss of DNA mismatch repair in acquired resistance to cisplatin.
Aebi S; Kurdi-Haidar B; Gordon R; Cenni B; Zheng H; Fink D; Christen RD; Boland CR; Koi M; Fishel R; Howell SB
Cancer Res; 1996 Jul; 56(13):3087-90. PubMed ID: 8674066
[TBL] [Abstract][Full Text] [Related]
13. Antisense inhibition of hMLH1 is not sufficient for loss of DNA mismatch repair function in the HCT116+chromosome 3 cell line.
Chauhan DP; Yang Q; Carethers JM; Marra G; Chang CL; Chamberlain SM; Boland CR
Clin Cancer Res; 2000 Oct; 6(10):3827-31. PubMed ID: 11051225
[TBL] [Abstract][Full Text] [Related]
14. Mismatch repair deficiency is associated with resistance to DNA minor groove alkylating agents.
Colella G; Marchini S; D'Incalci M; Brown R; Broggini M
Br J Cancer; 1999 May; 80(3-4):338-43. PubMed ID: 10408835
[TBL] [Abstract][Full Text] [Related]
15. The role of hMLH1, hMSH3, and hMSH6 defects in cisplatin and oxaliplatin resistance: correlation with replicative bypass of platinum-DNA adducts.
Vaisman A; Varchenko M; Umar A; Kunkel TA; Risinger JI; Barrett JC; Hamilton TC; Chaney SG
Cancer Res; 1998 Aug; 58(16):3579-85. PubMed ID: 9721864
[TBL] [Abstract][Full Text] [Related]
16. The role of DNA mismatch repair in platinum drug resistance.
Fink D; Nebel S; Aebi S; Zheng H; Cenni B; Nehmé A; Christen RD; Howell SB
Cancer Res; 1996 Nov; 56(21):4881-6. PubMed ID: 8895738
[TBL] [Abstract][Full Text] [Related]
17. Repair Defect in p21 WAF1/CIP1 -/- human cancer cells.
McDonald ER; Wu GS; Waldman T; El-Deiry WS
Cancer Res; 1996 May; 56(10):2250-5. PubMed ID: 8625293
[TBL] [Abstract][Full Text] [Related]
18. DNA mismatch repair (MMR) mediates 6-thioguanine genotoxicity by introducing single-strand breaks to signal a G2-M arrest in MMR-proficient RKO cells.
Yan T; Berry SE; Desai AB; Kinsella TJ
Clin Cancer Res; 2003 Jun; 9(6):2327-34. PubMed ID: 12796402
[TBL] [Abstract][Full Text] [Related]
19. Geldanamycin and its 17-allylamino-17-demethoxy analogue antagonize the action of Cisplatin in human colon adenocarcinoma cells: differential caspase activation as a basis for interaction.
Vasilevskaya IA; Rakitina TV; O'Dwyer PJ
Cancer Res; 2003 Jun; 63(12):3241-6. PubMed ID: 12810654
[TBL] [Abstract][Full Text] [Related]
20. Defective expression of the DNA mismatch repair protein, MLH1, alters G2-M cell cycle checkpoint arrest following ionizing radiation.
Davis TW; Wilson-Van Patten C; Meyers M; Kunugi KA; Cuthill S; Reznikoff C; Garces C; Boland CR; Kinsella TJ; Fishel R; Boothman DA
Cancer Res; 1998 Feb; 58(4):767-78. PubMed ID: 9485033
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
